Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 07, 2023

Efficacy and Safety of Dalpiciclib and Pyrotinib Combination Therapy in Women With HER2-Positive Advanced Breast Cancer

Nature Communications


Additional Info

Nature Communications
Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
Nat Commun 2023 Oct 07;14(1)6272, M Yan, L Niu, H Lv, M Zhang, J Wang, Z Liu, X Chen, Z Lu, C Zhang, H Zeng, S Zhao, Y Feng, H Sun, H Li

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading